Search

Your search keyword '"A. Barletta"' showing total 38 results

Search Constraints

Start Over You searched for: Author "A. Barletta" Remove constraint Author: "A. Barletta" Journal journal of thoracic oncology Remove constraint Journal: journal of thoracic oncology
38 results on '"A. Barletta"'

Search Results

1. 66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)

3. EP08.01-088 Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C

4. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

5. Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial

8. 192TiP Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: Diagnostic implications and prognostic role (BRAIN Lung study)

9. 192TiP Radiological morphological (MF) and radiomic features (RF) of brain metastases in oncogene-addicted advanced non-small cell lung cancer (NSCLC) patients: Diagnostic implications and prognostic role (BRAIN Lung study)

10. P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)

11. P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)

12. P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer

13. P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab

14. P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab

16. P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer

17. Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma

18. P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab

19. P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer

20. P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab

21. P3.02c-039 Endocrinological Side-Effects of Nivolumab in Advanced Non-Small Cell Lung Cancer

22. P3.02c-072 Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer

23. MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response

24. P3.02c-054 Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab

25. MA10.11 Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer

26. P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

27. P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

29. P3.02c-077 Cardiac Troponin-I Elevation in Patients with Non-Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab

30. P3.02c-054 Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab

31. P3.02c-072 Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer

32. P3.02c-074 Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer

33. P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab

34. MA10.11 Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer

35. MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response

36. P3.02c-074 Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer

37. P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab

38. P3.02c-077 Cardiac Troponin-I Elevation in Patients with Non-Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab

Catalog

Books, media, physical & digital resources